CoChat

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Open access
Shalabi, Haneen, Qin, Haiying, Su, Angela, Yates, Bonnie, Wolters, Pamela L., Steinberg, Seth M., Ligon, John A., Silbert, Sara, DéDé, Kniya, Benzaoui, Mehdi, Goldberg, Sophia, Achar, Sooraj, Schneider, Dina, Shahani, Shilpa A., Little, Lauren, Foley, Toni, Molina, John C., Panch, Sandhya, Mackall, Crystal L., Lee, Daniel W., Chien, Christopher D., Pouzolles, Marie, Ahlman, Mark, Yuan, Constance M., Wang, Hao-Wei, Wang, Yanyu, Inglefield, Jon, Toledo-Tamula, Mary Anne, Martin, Staci, Highfill, Steven L., Altan-Bonnet, Gregoire, Stroncek, David, Fry, Terry J., Taylor, Naomi, Shah, Nirali N. · 2022 · Blood
Cited by 162

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells is limited by antigen modulation, which may be overcome with combinatorial targeting. Building upon our experiences targeting CD19 and CD22 in B-cell acute lymphoblastic leukemia (B-ALL), we report on our phase 1 dose-escalation study of a novel murine stem cell virus (MSCV)-CD19/CD22-4-1BB bivalent CAR T-cell (CD19.22.BBζ) for children and young adults (CAYA) with B-cell malignancies. Primary objectives included toxicity and dose finding. Secondary objectives included response rates and relapse-free survival (RFS). Biologic correlatives included laboratory investigations, CAR T-cell expansion and cytokine profiling. Twenty patients, ages 5.4 to 34.6 years, with B-ALL received CD19.22.BBζ. The complete response (CR) rate was 60% (12 of 20) in the full cohort and 71.4% (10 of 14) in CAR-naïve patients. Ten (50%) developed cytokine release syndrome (CRS), with 3 (15%) having ≥ grade 3 CRS and only 1 experiencing neurotoxicity (grade 3). The 6- and 12-month RFS in those achieving CR was 80.8% (95% confidence interval [CI]: 42.4%-94.9%) and 57.7% (95% CI: 22.1%-81.9%), respectively. Limited CAR T-cell expansion and persistence of MSCV-CD19.22.BBζ compared with EF1α-CD22.BBζ prompted laboratory investigations comparing EF1α vs MSCV promoters, which did not reveal major differences. Limited CD22 targeting with CD19.22.BBζ, as evaluated by ex vivo cytokine secretion and leukemia eradication in humanized mice, led to development of a novel bicistronic CD19.28ζ/CD22.BBζ construct with enhanced cytokine production against CD22. With demonstrated safety and efficacy of CD19.22.BBζ in a heavily pretreated CAYA B-ALL cohort, further optimization of combinatorial antigen targeting serves to overcome identified limitations (www.clinicaltrials.gov #NCT03448393).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2022015795

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 162

Metadata

Authors
Shalabi, H., Qin, H., Su, A., Yates, B., Wolters, P. L., Steinberg, S. M., Ligon, J. A., Silbert, S., DéDé, K., Benzaoui, M., Goldberg, S., Achar, S., Schneider, D., Shahani, S. A., Little, L., Foley, T., Molina, J. C., Panch, S., Mackall, C. L., Lee, D. W., Chien, C. D., Pouzolles, M., Ahlman, M., Yuan, C. M., Wang, H.-W., Wang, Y., Inglefield, J., Toledo-Tamula, M. A., Martin, S., Highfill, S. L., Altan-Bonnet, G., Stroncek, D., Fry, T. J., Taylor, N., & Shah, N. N.
Venue
Blood
Published
2022-08-04
Volume
140
Issue
5
Pages
451-463
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4281398912
Cited by
162
References
40
FWCI
12.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. https://app.cochat.ai/papers/10.1182/blood.2022015795
The paper
Shalabi, H., Qin, H., Su, A., Yates, B., Wolters, P. L., Steinberg, S. M., Ligon, J. A., Silbert, S., DéDé, K., Benzaoui, M., Goldberg, S., Achar, S., Schneider, D., Shahani, S. A., Little, L., Foley, T., Molina, J. C., Panch, S., Mackall, C. L., . . . Shah, N. N. (2022). CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood. https://doi.org/10.1182/blood.2022015795

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.